PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31535830-13 2019 Angiotensinogen/Ang II levels in heart were unaffected by renal I/R, but they were significantly decreased after treatment with losartan and enalapril, whereas increase in renin levels decreased. Enalapril 141-150 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 0-15 19893496-7 2010 RESULTS: MAP was higher in male mice than female mice treated with enalapril and Ang II (male: 144 +/- 3 vs. female: 121 +/- 6 mm Hg, P < 0.05) and was not different between mice treated with enalapril alone (male: 99 +/- 3 vs. female: 100 +/- 3 mm Hg). Enalapril 195-204 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 81-87 19258495-8 2009 Interestingly, ACE inhibition (enalapril) and ANG II AT(1) receptor blocker (losartan) reduced intima thickening in 3-copy mice to 1-copy mouse values (P < 0.05) while ANG II treatment significantly increased intima thickening in 1-copy mice to 3-copy mouse levels (P < 0.05). Enalapril 31-40 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 171-177 15585195-0 2005 Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation. Enalapril 0-9 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 21-35 15585195-3 2005 This study was undertaken to determine whether enalapril, an ACE inhibitor, prevents atherosclerosis and vascular inflammation induced by Ang II in apolipoprotein E-deficient (apoE-KO) mice. Enalapril 47-56 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 138-144 15585195-7 2005 In addition to preventing the Ang II-induced over-expression of adhesion molecules and chemokines in the aorta, enalapril up-regulated the expression of peroxisome proliferator-activated receptors (PPARs)-alpha and -gamma, potential anti-inflammatory transcription factors. Enalapril 112-121 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 30-36 14597675-4 2003 We demonstrate that a decrease in the amount of circulating ANG II by the angiotensin-converting enzyme (ACE) inhibitor enalapril or the AT1 receptor antagonist losartan induced a stimulation of in vivo angiogenesis implying an inhibitory function of ANG II through the AT1 receptor. Enalapril 120-129 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 60-66 14597675-4 2003 We demonstrate that a decrease in the amount of circulating ANG II by the angiotensin-converting enzyme (ACE) inhibitor enalapril or the AT1 receptor antagonist losartan induced a stimulation of in vivo angiogenesis implying an inhibitory function of ANG II through the AT1 receptor. Enalapril 120-129 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 251-257 23846498-4 2013 Coinfusion of an ACE inhibitor, enalapril, ablated angiotensin I-augmented atherosclerosis but had no effect on angiotensin II-induced lesion development. Enalapril 32-41 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 51-64 21622682-7 2011 Ang I + CMP48/80 induced enhanced leucocyte adhesion that was attenuated by losartan, enalapril, enalapril + chymostatin, and cromolyn (a mast cell stabilizer). Enalapril 86-95 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 0-5 21622682-7 2011 Ang I + CMP48/80 induced enhanced leucocyte adhesion that was attenuated by losartan, enalapril, enalapril + chymostatin, and cromolyn (a mast cell stabilizer). Enalapril 97-106 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 0-5 8941574-7 1996 In addition, the role of Ang II in this model was studied by preventing the formation of Ang II with the angiotensin-converting enzyme inhibitor enalapril or by blocking of the Ang II receptor with the AT1 receptor antagonist losartan. Enalapril 145-154 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 89-95 8941574-7 1996 In addition, the role of Ang II in this model was studied by preventing the formation of Ang II with the angiotensin-converting enzyme inhibitor enalapril or by blocking of the Ang II receptor with the AT1 receptor antagonist losartan. Enalapril 145-154 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 89-95 33224383-12 2020 Conclusions: SAC/VAL, valsartan and enalapril all attenuated cardiomyocyte hypertrophy in a mouse model of Ang II-induced cardiac hypertrophy. Enalapril 36-45 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 107-113 31535830-13 2019 Angiotensinogen/Ang II levels in heart were unaffected by renal I/R, but they were significantly decreased after treatment with losartan and enalapril, whereas increase in renin levels decreased. Enalapril 141-150 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 16-22